Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
RAFAEL HOLDINGS, INC.
AI Executive Summary
AI-powered analysis of 8-K filing content
Rafael Holdings' subsidiary Cyclo Therapeutics entered an exclusive licensing agreement with MIT for a patent covering cyclodextrin use in Alzheimer's patients with the ApoE4 genetic mutation, strengthening the company's biotechnology portfolio and R&D capabilities in neurodegenerative disease treatment.
Key Takeaways
Cyclo Therapeutics secured exclusive U.S. rights to MIT Patent No. 12285440 for cyclodextrin-based Alzheimer's treatment targeting ApoE4 carriers
This partnership with a leading research institution enhances Rafael Holdings' competitive position in the Alzheimer's therapeutic market
1 more takeaway
Related Filings (1)
1 more filing from RAFAEL HOLDINGS, INC. in the last 90 days